MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

doi:10.1172/JCI67816

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

The Journal of clinical investigation - 1 May 2013

Schlegel Jennifer, Sambade Maria J, Sather Susan, Moschos Stergios J, Tan Aik-Choon, Winges Amanda, DeRyckere Deborah, Carson Craig C, Trembath Dimitri G, Tentler John J, Eckhardt S Gail, Kuan Pei-Fen, Hamilton Ronald L, Duncan Lyn M, Miller C Ryan, Nikolaishvili-Feinberg Nana, Midkiff Bentley R, Liu Jing, Zhang Weihe, Yang Chao, Wang Xiaodong, Frye Stephen V, Earp H Shelton, Shields Janiel M, Graham Douglas K

Abstract excerpt

Metastatic melanoma is one of the most aggressive forms of cutaneous cancers. Although recent therapeutic advances have prolonged patient survival, the prognosis remains dismal. C-MER proto-oncogene tyrosine kinase (MERTK) is a receptor tyrosine kinase with oncogenic properties that is often overexpressed or activated in various malignancies. Using both protein immunohistochemistry and microarray analyses, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to c-Mer Tyrosine Kinase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Intercellular Signaling Peptides and Proteins

Share to Melanocytes

Share to Mice, SCID

Share to Neoplasm Transplantation

Share to Proto-Oncogene Mas

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 23585477
DOI: 10.1172/JCI67816
PMCID: PMC3639697

Genes

MERTK
BRAF
GAS6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.PMID 23585477Read ↗

Targeting mutant NRAS signaling pathways in melanoma.Semantic proximity Read ↗

Trametinib (GSK1120212) in the treatment of melanomaSemantic proximity Read ↗

Trametinib in the treatment of melanoma.Semantic proximity Read ↗

Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction.Semantic proximity Read ↗

Identification of CRKL as an oncogenic biomarker for prognosis and immunotherapy in melanoma, and its potential molecular mechanismSemantic proximity Read ↗

Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.Semantic proximity Read ↗

Targeting activated KIT signaling for melanoma therapy.Semantic proximity Read ↗

BTK is a Prognostic Biomarker for Multiple Human TumorsSemantic proximity Read ↗

Receptor tyrosine kinases and their activation in melanoma.Semantic proximity Read ↗

Targeted therapies for cutaneous melanoma.Semantic proximity Read ↗

MERTK as a novel therapeutic target in head and neck cancer.Semantic proximity Read ↗

MERTK Inhibition as a Targeted Novel Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.